For instance, small-molecule inhibitors targeting only the secreted extracellular fraction of cathepsin D and not the lysosomal fraction had beneficial results in a rodent model of NAFLD [162]. Here, CTSD is linked to metabolic dysfunction-associated steatotic liver disease.